Dover Advisors LLC Has $413,000 Position in Zoetis Inc. (NYSE:ZTS)

Dover Advisors LLC lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 19.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,095 shares of the company’s stock after selling 512 shares during the quarter. Dover Advisors LLC’s holdings in Zoetis were worth $413,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Wellington Management Group LLP raised its position in shares of Zoetis by 2.5% during the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock worth $2,147,730,000 after purchasing an additional 297,044 shares during the period. Northern Trust Corp raised its position in Zoetis by 3.3% in the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock valued at $1,068,804,000 after buying an additional 196,771 shares during the last quarter. Bank of New York Mellon Corp raised its position in Zoetis by 3.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,998,989 shares of the company’s stock valued at $695,744,000 after buying an additional 150,918 shares during the last quarter. Royal Bank of Canada raised its position in Zoetis by 3.1% in the 3rd quarter. Royal Bank of Canada now owns 3,026,518 shares of the company’s stock valued at $526,553,000 after buying an additional 91,713 shares during the last quarter. Finally, Blair William & Co. IL raised its position in Zoetis by 1.4% in the 3rd quarter. Blair William & Co. IL now owns 2,428,509 shares of the company’s stock valued at $422,512,000 after buying an additional 32,918 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZTS. Barclays dropped their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Stifel Nicolaus dropped their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Piper Sandler reissued an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, The Goldman Sachs Group raised their price target on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $218.00.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 2,209 shares of company stock worth $371,293. 0.12% of the stock is owned by company insiders.

Zoetis Stock Up 3.3 %

ZTS stock traded up $5.06 during mid-day trading on Friday, reaching $158.42. The company had a trading volume of 5,236,463 shares, compared to its average volume of 4,019,007. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The stock has a 50 day simple moving average of $171.79 and a two-hundred day simple moving average of $179.33. The company has a market capitalization of $72.45 billion, a price-to-earnings ratio of 31.25, a PEG ratio of 2.42 and a beta of 0.85. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter in the prior year, the firm posted $1.15 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. As a group, equities analysts predict that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.09%. Zoetis’s dividend payout ratio is currently 34.12%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.